UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of June 2013

Commission File No.:001-35773

REDHILL BIOPHARMA LTD.

(Translation of registrant’s name into English)

21 Ha'arba'a Street, Tel Aviv, 64739, Israel

 (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. 

Form 20-F [X]   Form 40-F [  ]

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ 

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ 

Mr. Guy Goldberg, Chief Business Officer, presented an overview of the Company at the Jefferies 2013 Global Healthcare Conference held in New York City on Monday, June 3, 2013. A copy of the presentation made by the Company as well as a webcast replay of the presentation have been archived on the Company's website and may be viewed at the following web address: http://ir.redhillbio.com/events.cfm. The webcast replay will be available on RedHill's website for 30 days.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

		REDHILL BIOPHARMA LTD.
		(the "Registrant")
Date: June 4, 2013	By:	/s/ Dror Ben-Asher
		Dror Ben-Asher
		Chief Executive Officer